Related Experiment Video
Updated: Mar 13, 2026
Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
An Open-labeled, Multicenter Phase II Study of Tamibarotene in Patients with Steroid-refractory Chronic
Yoshinobu Maeda1, Hisakazu Nishimori, Yoshihiro Inamoto
1Department of Hematology and Oncology, Okayama University Hospital, Okayama 700-8558, Japan.yosmaeda@md.okayama-u.ac.jp.
Abstract:
Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020